Abstract
Glucose-dependent insulinotropic polypeptide (GIP) acts as a glucose-dependent growth factor for beta-cells. Here we show that GIP and glucose also act synergistically as anti-apoptotic factors for beta-cells, using the well-differentiated beta-cell line, INS-1. Mitogenic and anti-apoptotic signaling of GIP were dependent upon pleiotropic activation of protein kinase A (PKA)/cAMP regulatory element binder (CREB), mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3-kinase)/PKB signaling modules. The signaling modules activated by GIP were dependent on glucose metabolism and calcium influx and were tightly linked by multiple activating and inhibiting cross-talk. These interactions included: (i) a central role of tyrosine phosphorylation for stimulation of PKA/CREB, MAPK and PI3-kinase/PKB, (ii) inhibition of PKA/CREB by the MAPK pathway at the level of MAPK kinase-1 or downstream, (iii) activation of MAPK signaling by PI3-kinase and PKA at the level of extracellular-signal regulated kinase 1/2 or upstream, and (iv) activation of PKB by MAPK and PKA signaling at the level of PKB or upstream. Furthermore, we demonstrated inhibition of CREB signaling by Ca(2+)/calmodulin kinase I/IV. These results indicated that GIP acts as a mitogenic and anti-apoptotic factor for beta-cells by pleiotropic activation of tightly linked signaling pathways in beta-cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives*
-
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
-
Alloxan / pharmacology
-
Androstadienes / pharmacology
-
Apoptosis / drug effects
-
Arginase / genetics
-
B-Lymphocytes / metabolism*
-
Benzylamines / pharmacology
-
Calcium / metabolism
-
Calcium-Calmodulin-Dependent Protein Kinases / antagonists & inhibitors
-
Cell Line
-
Chelating Agents / pharmacology
-
Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
-
Deoxyglucose / pharmacology
-
Egtazic Acid / pharmacology
-
Enzyme Inhibitors / pharmacology
-
Flavonoids / pharmacology
-
Gastric Inhibitory Polypeptide / pharmacology*
-
Genistein / pharmacology
-
Glucokinase / antagonists & inhibitors
-
Glucose / metabolism
-
Humans
-
Indoles / pharmacology
-
Isoquinolines / pharmacology
-
MAP Kinase Kinase 1
-
MAP Kinase Signaling System / drug effects
-
Maleimides / pharmacology
-
Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
-
Mitosis / drug effects*
-
Phosphoinositide-3 Kinase Inhibitors
-
Plasmids
-
Protein Kinase C / antagonists & inhibitors
-
Protein Serine-Threonine Kinases / antagonists & inhibitors
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Signal Transduction / drug effects*
-
Sulfonamides / pharmacology
-
Wortmannin
Substances
-
Androstadienes
-
Benzylamines
-
Chelating Agents
-
Enzyme Inhibitors
-
Flavonoids
-
Indoles
-
Isoquinolines
-
Maleimides
-
Phosphoinositide-3 Kinase Inhibitors
-
Sulfonamides
-
KN 93
-
Egtazic Acid
-
Gastric Inhibitory Polypeptide
-
KN 62
-
Alloxan
-
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
-
Deoxyglucose
-
Genistein
-
Glucokinase
-
Protein-Tyrosine Kinases
-
Protein Serine-Threonine Kinases
-
Cyclic AMP-Dependent Protein Kinases
-
Protein Kinase C
-
Calcium-Calmodulin-Dependent Protein Kinases
-
MAP Kinase Kinase 1
-
MAP2K1 protein, human
-
Mitogen-Activated Protein Kinase Kinases
-
Arginase
-
Glucose
-
bisindolylmaleimide I
-
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
-
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
-
Calcium
-
Wortmannin